BOSTON, March 25, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (RNAZ), ("TransCode" or the "Company"), the RNA oncology company committed to more effectively treating cancer using RNA ...
15 patients treated across four escalating dose levels of TTX-MC138 No significant safety or dose limiting toxicities reported 10 patients remain on study with no evidence of disease progression PD ...
Follows Safety Review Committee (SRC) approval based on safety data from patients in Cohorts 1 and 2 No significant safety or dose limiting toxicities reported in Cohorts 1 and 2 PK data from Cohorts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback